Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SANGUINE CORP. (SGNC) -- Ignore unavailable to you. Want to Upgrade?

To: Prospector who wrote (3984)	9/16/1998 11:42:00 AM
From: RBM	Read Replies (2) \| Respond to of 5402

Prospector and all, Howdy all. I am sorry I don't contribute much here, but I have enough going on other places and it is safe to say I am a SGNC shareholder :-) Today I will contribute a little: Baxter sets Q3 charges, drops HemAssist product DEERFIELD, Ill., Sept 16 (Reuters) - Baxter Healthcare Corp. (NYSE:BAX - news) said Wednesday it would take third quarter charges of $178 million related to breast implant litigation and $75 million to drop development of its blood substitute product, HemAssist, which is derived from human hemoglobin. The company also said it anticipates taking a third-quarter charge against net earnings of about $40 million, primarily for the write down of certain minority investments and the dissolution of certain joint ventures. The company said it has decided to focus its research-and-development efforts in oxygen-carrying therapeutics, or ''blood substitutes,'' on its second-generation program, which is based on genetically engineered hemoglobin molecules. Ending its development of HemAssist will force the company to eliminate about 100 jobs worldwide. The company said it would offer some of those employees jobs developing the second generation program or in its other businesses. Baxter halted its Phase III U.S. clinical trial of HemaAssist in February because it noticed higher mortality rates among patients using HemaAssist than those given a placebo, prompting Baxter to determine the results to be inconclusive, Baxter spokeswoman, Mary Thomas said. She said The company halted the European clincal trial of the product in June because of concerns about the drug's safety and efficacy. Baxter said in its statement that it will modify its manufacturing facility in Neuchatel, Switzerland, which was designed to manufacture a human hemoglobin product, to produce other Baxter biopharmaceutical products. While we're disappointed, delays are sometimes part of the process of developing breakthrough medical therapies such as oxygen-carrying therapeutics," said Harry Jansen Kraemer, Baxter's president. Kraemer described halting the development of HemAssist as ''a difficult decision,'' but said it wasn't clear whether its market value would have outweighed development costs. First call analysts' consensus put Baxter's earnings at $0.61 per share for the third quarter.

To: Prospector who wrote (3984)	9/16/1998 11:46:00 AM
From: Mike P.	Respond to of 5402

yes, ive tried to get a call into mary to explain that its time steve gets a raise. business unusual, dobbs is like the ef hutton of financial tv, very cool. throws a bunch of softballs at guests as well leaving them every opportunity to plug their company for the world while he just sits there and goes 'wow, hey thats neat'. didnt think we were getting a batelle update till october, thanks for the heads up. poet thinking he wouldnt like to be one of the guinea's given a placebo.